Risk Factors Associated with Uncomplicated Peptic Ulcer and Changes in Medication Use after Diagnosis

Antonio González-Pérez¹,², María E. Sáez¹,², Saga Johansson³, Péter Nagy³, Luis A. García Rodríguez¹*

¹ The Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain, ² Andalusian Bioinformatics Research Centre (CAEBi), Seville, Spain, ³ AstraZeneca R&D, Mölndal, Sweden

Abstract

Background: Few epidemiologic studies have investigated predictors of uncomplicated peptic ulcer disease (PUD) separately from predictors of complicated PUD.

Objective: To analyze risk factors associated with uncomplicated PUD and medication use after diagnosis.

Methods: Patients diagnosed with uncomplicated PUD (n = 3,914) were identified from The Health Improvement Network database among individuals aged 40–84 years during 1997–2005, with no previous history of PUD. Prescription records for the year after the date of diagnosis were reviewed and a nested case–control analysis was performed to calculate the odds ratios for the association of potential risk factors with PUD.

Results: Medications associated with developing uncomplicated PUD included current use of acetylsalicylic acid (ASA), nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, selective serotonin reuptake inhibitors, antidepressants, antihypertensives or acid suppressants. Uncomplicated PUD was significantly associated with being a current or former smoker and having had a score of at least 3 on the Townsend deprivation index. Approximately 50% of patients who were users of ASA (19% of patients) or chronic users of NSAIDs (7% of patients) at diagnosis did not receive another prescription of the medication in the 60 days after diagnosis, and 30% were not represcribed therapy within a year. Among patients who were current users of ASA or chronic NSAIDs at the time of the PUD diagnosis and received a subsequent prescription for their ASA or NSAID during the following year, the vast majority (80–90%) also received a proton pump inhibitor coprescription.

Conclusions: Our results indicate that several risk factors for upper gastrointestinal bleeding are also predictors of uncomplicated PUD, and that some patients do not restart therapy with ASA or NSAIDs after a diagnosis of uncomplicated PUD. Further investigation is needed regarding the consequences for these patients in terms of increased cardiovascular burden due to discontinuation of antiplatelet therapy.

Citation: González-Pérez A, Sáez ME, Johansson S, Nagy P, García Rodríguez LA (2014) Risk Factors Associated with Uncomplicated Peptic Ulcer and Changes in Medication Use after Diagnosis. PloS ONE 9(7): e101768. doi:10.1371/journal.pone.0101768

Editor: Markus M. Heimesaat, Charité, Campus Benjamin Franklin, Germany

Received February 28, 2014; Accepted June 11, 2014; Published July 8, 2014

Copyright: © 2014 González-Pérez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was funded by AstraZeneca R&D, Mölndal, Sweden. Two of the manuscript authors, Saga Johansson and Péter Nagy, provided input on the design of the study, were involved in analysis and interpretation of the data and contributed fully to the development and finalization of the manuscript, and approved it for submission. Other employees of AstraZeneca were given the opportunity to comment on manuscript drafts and the authors gave consideration to any relevant comments received.

Competing Interests: Antonio González-Pérez, Luis A. García Rodriguez, and Maria Eugenia Sáez work for CEIFE, which has received research funding from AstraZeneca R&D, Mölndal, Sweden and Bayer Pharma AG, Berlin, Germany. Luis A. García Rodriguez has received honoraria for serving on scientific advisory boards for AstraZeneca and Bayer. Saga Johansson and Péter Nagy are employees of AstraZeneca R&D, Mölndal, Sweden. Medical writing services from Carolyn Brechin PhD and Stephen Sweet PhD of Oxford PharmaGenesis Ltd, Oxford, UK, were funded by AstraZeneca. The declared potential competing interests do not alter the authors’ adherence to PLOS ONE policies on sharing data and materials.

* Email: lagarcia@ceife.es

Introduction

In the UK general population, it has been estimated that the incidence of peptic ulcer complications, including ulcer haemorrhage or perforation, is approximately 1 per 1000 person-years, and about 5–10% of these complications may be fatal [1–3]. Although the need for efficient identification and treatment of potentially life-threatening complications is clear, uncomplicated peptic ulcer disease (PUD) is also clinically relevant and contributes to the overall health burden of PUD. Complications may develop in patients with initially uncomplicated ulcer [4,5] and, even in the absence of overt bleeding, uncomplicated peptic ulcers may lead to the development of anemia [6]. Upper gastrointestinal (GI) symptoms potentially related to PUD affect patients’ health-related quality of life [7] and such symptoms have also been reported to affect patients’ use of acetylsalicylic acid (ASA) [8]. A recent observational study suggested that a history of uncomplicated PUD approximately doubles the probability of poor adherence to nonsteroidal anti-inflammatory drug (NSAID) therapy [9].

We have previously shown that, from 1997 to 2005, the overall incidence of uncomplicated PUD was 0.75 cases per 1000 person-years in a study conducted using The Health Improvement
Materials and Methods

Data Source

Data were collected from THIN, a computerized primary care database containing anonymized records for over 3 million individuals currently registered with participating primary care practices in the UK. Patients included in the database are representative of the general UK population with respect to age, sex and geographical region [16]. Information contained in THIN includes patient demographics, details of consultations with primary care physicians (PCPs), information about consultant referrals and hospitalizations, laboratory test results, diagnoses and prescriptions. Diagnoses and symptoms are recorded using Read codes [17]. The validity of THIN for use in pharmacoepidemiologic studies has been demonstrated [18].

Study Population

Selection of the study population has been described in detail elsewhere [10]. Briefly, patients were identified who were aged 40–84 years between January 1997 and December 2005, who had been enrolled with their PCP for at least 2 years and who had at least 1 year of computerized prescription history. The date when a patient met the inclusion criteria was that individual’s start date. Patients were excluded if they had received a diagnosis of cancer, Mallory–Weiss syndrome or PUD (complicated or uncomplicated), or if they had a history of upper GI bleeding, esophageal varices, alcohol abuse, liver disease or coagulopathies. Patients were also excluded if they were aged 70 years or over at their start date and had at least 1 year of follow-up with one or fewer data points recorded during that time (proxy for incomplete data recording). All remaining patients constituted the study population (N = 1,049,689).

Uncomplicated PUD Case Ascertainment and Control Population Selection

All patients in the study population were followed up until the end of the study period (December 2005) or until they reached the age of 85 years, died, met any of the exclusion criteria (including receiving a diagnosis of complicated PUD) or received a diagnosis of uncomplicated PUD. Of the individuals who had a Read code suggestive of a diagnosis of uncomplicated PUD, true cases (n = 3,914) were considered to be those for whom the diagnosis had been made during a specialist visit or hospitalization (typically involving endoscopy – the standard diagnostic technique in the UK) [10,19]. A random sample of 143 cases of uncomplicated PUD was used previously to demonstrate the positive predictive rate: 94% were confirmed as definite or possible cases [10]. In addition, 9,969 control individuals with no diagnosis of uncomplicated PUD were sampled from the whole study cohort using incidence density sampling, which is the method of choice for obtaining unbiased results in a nested case–control analysis [20].

It was observed that many (n = 1,764) of the patients who received a diagnosis of uncomplicated PUD had recorded upper GI symptoms (including nausea, vomiting, dyspepsia, heartburn and epigastric pain) before their date of PUD diagnosis. The mean length of time between early symptom appearance and diagnosis of uncomplicated PUD for all patients with such early symptoms was found to be 131 days. Based on these data, for all patients with uncomplicated PUD, the index date used for nested case–control analysis was 120 days (4 months) before the recorded date of diagnosis of uncomplicated PUD. For controls, the index date for nested case–control analysis was the randomly chosen date generated during the control selection process.

Data Collection and Analysis

In the present analysis (ClinicalTrials.gov: NCT01888388), for all cases and controls, demographic, lifestyle and comorbidity information was ascertained at the index date, as well as information on exposure to medications. Medication use was classified as current, recent, past and non-use as follows: current use, prescription active at the index date or ending in the 7 days before the index date; recent use, most recent prescription ending 8–30 days before the index date; past use, most recent prescription ending 31–365 days before the index date; and non-use, no recorded prescription or most recent prescription ending more than 365 days before the index date. The group of current ASA users was subdivided for particular analyses: naïve current ASA users were defined as those receiving ASA at the index date and having received their first ASA prescription during the study period after an interval of more than 365 days during which they received no ASA prescription. All other ASA users were defined as non-naïve.

Social deprivation was measured in all patients according to the Townsend deprivation index [21]. We were able to ascertain Helicobacter pylori infection status among patients with uncomplicated PUD, as described previously [10], but not among control individuals. Therefore, comparisons were made with the overall control group to estimate the risk of H. pylori positive and H. pylori negative uncomplicated PUD associated with use of different drugs. Nested case–control analyses were carried out using unconditional logistic regression analysis models, adjusted (when appropriate) for sex, age, year of index date, number of PCP visits and specialist referrals in the year before the index date, smoking status and use of gastroprotective drugs (proton pump inhibitors [PPIs] or histamine type 2 receptor antagonists [H2RAs]), paracetamol, ASA and NSAIDs. All statistical analyses were carried out using Stata SE (version 12.0; StataCorp, College Station, Texas, USA).

For patients who received an uncomplicated PUD diagnosis, ASA, NSAID and PPI use was also ascertained in the year following their date of diagnosis (as recorded in their medical records).
Table 1. Patient demographics and lifestyle characteristics at the index date, and comorbidities significantly associated with uncomplicated PUD development, in a UK primary care population during 1997–2005.

| Characteristic                  | Cases n = 3,914 | Controls n = 9,969 | Association* |
|---------------------------------|----------------|--------------------|--------------|
| **Sex**                         |                |                    |              |
| Male                            | 1,921 (49.1)   | 4,893 (49.1)       | NA           |
| Female                          | 1,993 (50.9)   | 5,076 (50.9)       | NA           |
| **Age, years**                  |                |                    |              |
| 40–49                           | 669 (17.1)     | 1,712 (17.2)       | NA           |
| 50–59                           | 896 (22.9)     | 2,276 (22.8)       | NA           |
| 60–69                           | 1,023 (26.1)   | 2,619 (26.3)       | NA           |
| 70–79                           | 1,030 (26.3)   | 2,601 (26.1)       | NA           |
| 80–84                           | 296 (7.5)      | 761 (7.6)          | NA           |
| **Smoking status**              |                |                    |              |
| Non-smoker                      | 1,725 (44.1)   | 5,292 (53.1)       | 1.00         |
| Smoker                          | 1,151 (29.4)   | 1,852 (18.6)       | 1.90 (1.72–2.10) |
| Former smoker                   | 680 (17.4)     | 1,431 (14.4)       | 1.30 (1.15–1.45) |
| Unknown                         | 358 (9.1)      | 1,394 (14.0)       | 0.97 (0.85–1.11) |
| **Alcohol use**                 |                |                    |              |
| None/occasional                 | 2,046 (52.3)   | 4,619 (46.3)       | 1.00         |
| Light                           | 856 (21.9)     | 2,430 (24.4)       | 0.86 (0.78–0.95) |
| Moderate                        | 199 (5.1)      | 473 (4.7)          | 0.97 (0.80–1.17) |
| Heavy                           | 133 (3.4)      | 332 (3.3)          | 0.86 (0.69–1.08) |
| Unknown                         | 680 (17.4)     | 2,115 (21.2)       | 1.00 (0.87–1.15) |
| **BMI, kg/m^2**                 |                |                    |              |
| <20                             | 161 (4.1)      | 337 (3.4)          | 1.16 (0.94–1.44) |
| 20–24                           | 1,066 (27.2)   | 2,744 (27.5)       | 1.00         |
| 25–29                           | 1,258 (32.1)   | 3,047 (30.6)       | 1.00 (0.90–1.11) |
| ≥30                             | 695 (17.8)     | 1,605 (16.1)       | 0.93 (0.82–1.05) |
| Unknown                         | 734 (18.8)     | 2,236 (22.4)       | 1.04 (0.91–1.19) |
| **PCP visits in the previous year** |            |                    |              |
| 0–1                             | 1,417 (36.2)   | 4,735 (47.5)       | 1.00         |
| 2–5                             | 1,463 (37.4)   | 3,537 (35.5)       | 1.17 (1.06–1.29) |
| ≥6                              | 1,034 (26.4)   | 1,697 (17.0)       | 1.48 (1.31–1.67) |
| **Specialist referrals in the previous year** |             |                    |              |
| 0                               | 2,685 (68.6)   | 7,822 (78.5)       | 1.00         |
| 1–2                             | 804 (20.5)     | 1,537 (15.4)       | 1.26 (1.13–1.40) |
| ≥3                              | 425 (10.9)     | 610 (6.1)          | 1.34 (1.16–1.56) |
| **Hospitalization in the previous year** |          |                    |              |
| 0                               | 3,688 (94.2)   | 9,657 (96.9)       | 1.00         |
| ≥1                              | 226 (5.8)      | 312 (3.1)          | 1.21 (0.99–1.48) |
| **Townsend deprivation index**  |                |                    |              |
| 0 (least deprived)              | 231 (5.9)      | 603 (6.0)          | 1.10 (0.91–1.32) |
| 1                               | 779 (19.9)     | 2,546 (25.5)       | 1.00         |
| 2                               | 792 (20.2)     | 2,227 (22.3)       | 1.08 (0.96–1.22) |
| 3                               | 782 (20.0)     | 1,926 (19.3)       | 1.16 (1.03–1.31) |
| 4                               | 741 (18.9)     | 1,573 (15.8)       | 1.27 (1.12–1.45) |
| 5 (most deprived)               | 589 (15.0)     | 1,094 (11.0)       | 1.35 (1.18–1.56) |
| **Comorbidities**               |                |                    |              |
| Stress                          | 246 (6.3)      | 430 (4.3)          | 1.23 (1.03–1.47) |
Table 1. Cont.

| Cases n = 3,914 | Controls n = 9,969 | Association* OR (95% CI) |
|----------------|-------------------|-------------------------|
| Depression     |                   |                         |
| 900 (23.0)     | 1,615 (16.2)      | 1.23 (1.11–1.36)        |
| GERD           |                   |                         |
| 716 (18.3)     | 971 (9.7)         | 1.19 (1.06–1.34)        |
| Upper GI symptomsd |               |                         |
| 2,050 (52.4)  | 2,845 (28.5)      | 1.88 (1.72–2.04)        |

Abbreviations: ASA, acetylsalicylic acid; BMI, body mass index; CI, confidence interval; GERD, gastroesophageal reflux disease; GI, gastrointestinal; H2RA, histamine type 2 receptor antagonist; NA, not applicable (controls were frequency-matched to cases by sex and age); NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; PCP, primary care physician; PPI, proton pump inhibitor; PUD, peptic ulcer disease.

aRelative to the indicated category, and adjusted when appropriate for sex, age, year of index date, number of PCP visits and specialist referrals in the year before the index date, smoking status, and use of gastroprotective drugs (PPIs or H2RAs), paracetamol, ASA and NSAIDs.

bNone/occasional, <3 units per week; light, 3–15 units per week; moderate, 16–24 units per week; heavy, ≥25 units per week.

cRelative to being free from the respective comorbidity. Only significantly associated comorbidities are listed.

dIncluding nausea, vomiting, dyspepsia, heartburn and epigastric pain.

doi:10.1371/journal.pone.0101768.t001

The analysis of data from the THIN database was approved by the Multicentre Research Ethics Committee (REC reference 07/MRE05/18) and patient records were anonymized and de-identified prior to analysis. All authors had access to the study data and reviewed and approved the final manuscript.

Results

Patient Characteristics and Comorbidities

The demographics and lifestyle characteristics at the index date for the 3,914 patients who received a diagnosis of uncomplicated PUD during the study period and the 9,969 controls are shown in Table 1, along with comorbidities significantly associated with the development of uncomplicated PUD (the unadjusted odds ratios [OR] are presented in Table S1). Uncomplicated PUD was significantly associated with being a current or former smoker, having had at least two PCP visits or one or more specialist referrals in the year before the index date, and having had a score of at least 3 on the Townsend deprivation index. Among the comorbidities, stress, depression, gastroesophageal reflux disease and having upper GI symptoms (including nausea, vomiting, dyspepsia, heartburn and epigastric pain) were all significantly associated with uncomplicated PUD development.

Medication Use and the Risk of Uncomplicated PUD Development

Current use of ASA, NSAIDs, paracetamol, selective serotonin reuptake inhibitors, tricyclic antidepressants, antihypertensives or gastroprotective medications (PPIs and H2RAs) was associated with uncomplicated PUD development, relative to non-use (Table 2, the unadjusted values are presented in Table S2). For current use of ASA, the risk of uncomplicated PUD was increased 1.5-fold (OR: 1.54; 95% confidence interval [CI]: 1.37–1.74), while dual antipilet therapy (ASA and clopidogrel) was associated with an approximately 2.5-fold increased risk (OR: 2.62; 95% CI: 1.12–6.11).

Dose, Duration of Treatment, and Number of Medications. For NSAIDs, the association was stronger in current users of multiple NSAIDs (OR: 3.82; 95% CI: 2.16–6.73) than in current users of only a single NSAID (OR: 1.64; 95% CI: 1.43–1.87), and increased with increasing duration of treatment (OR: 2.46; 95% CI: 1.92–3.16 for use of >3 years, versus OR: 1.07; 95% CI: 0.84–1.35 for use of <3 months). Current users of ASA<100 mg had a similar risk to those who received ASA 150–300 mg (<100 mg OR: 1.52; 95% CI: 1.33–1.73; 100–200 mg OR: 1.61; 95% CI: 1.27–2.04; and 200–300 mg OR: 1.70; 95% CI: 1.12–2.57). The risk of developing uncomplicated PUD was elevated whether patients had received ASA for less than 3 months or longer than 3 years (OR: 1.82; 95% CI: 1.38–2.41; and OR: 1.53; 95% CI: 1.26–1.86, respectively). ORs for the risk of developing uncomplicated PUD were 1.50 (95% CI: 1.29–1.75) and 2.41 (95% CI: 1.25–4.63) in naive and non-naive users of ASA, respectively. An association was also apparent between uncomplicated PUD development and current use of oral corticosteroids with duration of longer than 3 years (OR: 1.92; 95% CI: 1.04–3.53).

Gastric and Duodenal Ulcers. The association between medication use and uncomplicated PUD development was also analyzed according to ulcer location (Table 3, the unadjusted values are presented in Table S3). Current use of ASA was associated with an increased risk of uncomplicated gastric ulcer (OR: 1.69; 95% CI: 1.45–1.96) and of uncomplicated duodenal ulcer (OR: 1.36; 95% CI: 1.16–1.61). Current use of NSAIDs was more strongly associated with the development of uncomplicated gastric ulcer than with uncomplicated duodenal ulcer, and the results indicated that oral antiacid use may be associated with uncomplicated gastric ulcer, but not uncomplicated duodenal ulcer.

Helicobacter Pylori Infection Status. Among cases of uncomplicated PUD, 1,333 patients were determined to be positive for H. pylori, 368 patients were determined to be negative for H. pylori, and infection status was unknown in 2,213 patients. Medication use significantly associated with an increased risk of developing uncomplicated PUD in patients positive or negative for H. pylori is presented in Table S4. The results should be interpreted with caution, given that it is not possible to ascertain the rationale for whether or not H. pylori status was determined among patients in the database, and infection status was not available for control individuals.

Gastroprotective Medication. It was reasoned that the positive association between uncomplicated PUD development and the use of PPIs and H2RAs was probably due to confounding by indication (i.e. the fact that these medications are used to treat upper GI symptoms and complications). To test this hypothesis, we analyzed the association between PPI use and the risk of uncomplicated PUD development in the subgroup of naive users of ASA. Naive current users of ASA were split into three groups: those who did not receive a PPI prescription at any point between
their first ASA prescription and their index date (non-users); those who were prescribed a PPI at the same time as their first ASA prescription; and those who were not prescribed a PPI at the time of first ASA prescription but received a PPI prescription afterwards.

Patients who received a PPI prescription sometime after their first ASA prescription had a significantly increased risk of developing uncomplicated PUD compared with non-users of a PPI (OR: 2.29; 95% CI: 1.45–3.63). In contrast, this association was not apparent among patients who received a PPI at the same time as their first ASA prescription, compared with non-users of a PPI (OR: 0.86; 95% CI: 0.42–1.78 for patients with continuous PPI use until the index date) (Table 4, the unadjusted values are presented in Table S5). These results suggest that PPI use does not

| Medication | Cases | Controls | Association* |
|------------|-------|----------|--------------|
| Current   | 725 (18.5) | 1,133 (11.4) | 1.54 (1.37–1.74) |
| Recent    | 65 (1.7) | 89 (0.9) | 1.74 (1.23–2.46) |
| Past      | 142 (3.6) | 233 (2.3) | 1.28 (1.01–1.61) |

| NSAIDs | Current | 560 (14.3) | 734 (7.4) | 1.70 (1.49–1.94) |
| Recent | 103 (2.6) | 212 (2.1) | 1.04 (0.80–1.34) |
| Past   | 560 (14.3) | 1,303 (13.1) | 1.03 (0.91–1.16) |

| Oral anticoagulants | Current | 85 (2.2) | 154 (1.5) | 1.21 (0.91–1.61) |
| Recent | 14 (0.4) | 27 (0.3) | 1.31 (0.66–2.62) |
| Past   | 32 (0.8) | 34 (0.3) | 1.81 (1.09–3.02) |

| Paracetamol | Current | 649 (16.6) | 868 (8.7) | 1.56 (1.38–1.78) |
| Recent | 190 (4.9) | 281 (2.8) | 1.45 (1.18–1.78) |
| Past   | 651 (16.6) | 1,140 (11.4) | 1.32 (1.17–1.49) |

| PPIs | Current | 451 (11.5) | 524 (5.3) | 2.05 (1.77–2.36) |
| Recent | 79 (2.0) | 53 (0.5) | 4.21 (2.92–6.08) |
| Past   | 334 (8.5) | 278 (2.8) | 2.89 (2.42–3.44) |

| H2RAs | Current | 261 (6.7) | 215 (2.2) | 2.99 (2.47–3.63) |
| Recent | 67 (1.7) | 34 (0.3) | 4.62 (2.99–7.12) |
| Past   | 344 (8.8) | 237 (2.4) | 3.25 (2.71–3.89) |

| SSRIs | Current | 159 (4.1) | 216 (2.2) | 1.37 (1.09–1.72) |
| Recent | 20 (0.5) | 52 (0.5) | 0.80 (0.46–1.38) |
| Past   | 108 (2.8) | 212 (2.1) | 0.92 (0.72–1.19) |

| Tricyclic antidepressants | Current | 205 (5.2) | 279 (2.8) | 1.29 (1.05–1.57) |
| Recent | 15 (0.4) | 34 (0.3) | 0.77 (0.39–1.49) |
| Past   | 145 (3.7) | 214 (2.1) | 1.28 (1.01–1.61) |

| Antihypertensives | Current | 1,494 (38.2) | 2,938 (29.5) | 1.13 (1.02–1.26) |
| Recent | 68 (1.7) | 186 (1.9) | 0.82 (0.60–1.11) |
| Past   | 165 (4.2) | 310 (3.1) | 1.27 (1.03–1.57) |

Abbreviations: ASA, acetylsalicylic acid; CI, confidence interval; H2RA, histamine type 2 receptor antagonist; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; PCP, primary care physician; PPI, proton pump inhibitor; PUD, peptic ulcer disease; SSRi, selective serotonin reuptake inhibitor.

*Relative to non-use. Adjusted (when appropriate) according to sex, age, year of index date, number of PCP visits and specialist referrals in the year before the index date, smoking status, and use of gastroprotective drugs (PPIs or H2RAs), paracetamol, ASA and NSAIDs.
increase the risk of uncomplicated PUD and that the observed association with uncomplicated PUD is due to PPI prescription to treat upper GI symptoms, possibly associated with undiagnosed PUD.

### Table 3. Medications for which current, past or recent use was significantly associated with uncomplicated PUD development when stratified by ulcer location (gastric or duodenal), in a UK primary care population during 1997–2005.

| Medication Type | Uncomplicated Gastric Ulcer | Uncomplicated Duodenal Ulcer |
|-----------------|-----------------------------|-----------------------------|
|                 | Cases                       | Controls                    | Association                        | Cases                       | Controls                    | Association                        |
|                 | n = 1,688                   | n = 9,969                   | n (%)                           | OR (95% CI)                        | n = 1,721                   | n = 9,969                   | n (%)                           | OR (95% CI)                        |
| ASA             |                             |                             |                                 |                                  |                             |                             |                                 |                                  |
| Current         | 376 (22.3)                  | 1,133 (11.4)                | 1.69 (1.45–1.96)                | 274 (15.9)                       | 1,133 (11.4)                | 1.36 (1.16–1.61)             |                                 |                                  |
| Recent          | 35 (2.1)                    | 89 (0.9)                    | 2.13 (1.39–3.25)                | 24 (1.4)                        | 89 (0.9)                    | 1.46 (0.90–2.37)             |                                 |                                  |
| Past            | 69 (4.1)                    | 233 (2.3)                   | 1.34 (0.99–1.79)                | 53 (3.1)                        | 233 (2.3)                   | 1.11 (0.80–1.54)             |                                 |                                  |
| NSAIDs          |                             |                             |                                 |                                  |                             |                             |                                 |                                  |
| Current         | 309 (18.3)                  | 734 (7.4)                   | 1.98 (1.68–2.33)                | 185 (10.7)                       | 734 (7.4)                   | 1.36 (1.13–1.64)             |                                 |                                  |
| Recent          | 51 (3.0)                    | 212 (2.1)                   | 1.10 (0.79–1.53)                | 35 (2.0)                        | 212 (2.1)                   | 0.82 (0.56–1.21)             |                                 |                                  |
| Past            | 251 (14.9)                  | 1,303 (13.1)                | 1.07 (0.91–1.26)                | 245 (14.2)                       | 1,303 (13.1)                | 1.00 (0.85–1.18)             |                                 |                                  |
| Oral anticoagulants |                         |                             |                                 |                                  |                             |                             |                                 |                                  |
| Current         | 47 (2.8)                    | 154 (1.5)                   | 1.44 (1.01–2.06)                | 29 (1.7)                        | 154 (1.5)                   | 1.02 (0.66–1.55)             |                                 |                                  |
| Recent          | 9 (0.5)                     | 27 (0.3)                    | 2.31 (1.04–5.10)                | 4 (0.2)                         | 27 (0.3)                    | 0.70 (0.23–2.16)             |                                 |                                  |
| Past            | 20 (1.2)                    | 34 (0.3)                    | 2.44 (1.36–4.40)                | 7 (0.4)                         | 34 (0.3)                    | 0.99 (0.42–2.29)             |                                 |                                  |
| PPIs            |                             |                             |                                 |                                  |                             |                             |                                 |                                  |
| Current         | 207 (12.3)                  | 524 (5.3)                   | 1.84 (1.53–2.22)                | 180 (10.5)                       | 524 (5.3)                   | 2.03 (1.68–2.47)             |                                 |                                  |
| Recent          | 33 (2.0)                    | 53 (0.5)                    | 3.52 (2.21–5.61)                | 35 (2.0)                        | 53 (0.5)                    | 4.56 (2.89–7.21)             |                                 |                                  |
| Past            | 145 (8.6)                   | 278 (2.8)                   | 2.65 (2.12–3.31)                | 145 (8.4)                       | 278 (2.8)                   | 2.97 (2.37–3.73)             |                                 |                                  |
| H2RAs           |                             |                             |                                 |                                  |                             |                             |                                 |                                  |
| Current         | 118 (7.0)                   | 215 (2.2)                   | 2.77 (2.17–3.54)                | 120 (7.0)                       | 215 (2.2)                   | 3.44 (2.70–4.37)             |                                 |                                  |
| Recent          | 29 (1.7)                    | 34 (0.3)                    | 3.90 (2.30–6.64)                | 31 (1.8)                        | 34 (0.3)                    | 5.43 (3.26–9.05)             |                                 |                                  |
| Past            | 133 (7.9)                   | 237 (2.4)                   | 2.59 (2.05–3.28)                | 177 (10.3)                       | 237 (2.4)                   | 3.83 (3.09–4.75)             |                                 |                                  |

Abbreviations: ASA, acetylsalicylic acid; CI, confidence interval; H2RA, histamine type 2 receptor antagonist; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; PCP, primary care physician; PPI, proton pump inhibitor; PUD, peptic ulcer disease.

aData are presented for all cases for which ulcer location (gastric or duodenal) was recorded.

bRelative to non-use. Adjusted (when appropriate) according to sex, age, year of index date, number of PCP visits and specialist referrals in the year before the index date, smoking status, and use of gastroprotective drugs (PPIs or H2RAs), paracetamol, ASA and NSAIDs.

doi:10.1371/journal.pone.0101768.t003

### Table 4. Association between PPI use and uncomplicated PUD development in naive current ASA users in a UK primary care population during 1997–2005.

| Medication Type | Cases | Controls | Association |
|-----------------|-------|----------|-------------|
|                 | n = 350 | n = 541 | OR (95% CI) |

| Type                | n (%) | n (%) | OR (95% CI) |
|---------------------|-------|-------|-------------|
| No PPI              | 253 (72.3) | 452 (83.5) | 1.00        |
| PPI at first ASA prescription | 38 (10.9) | 49 (9.1) | 1.27 (0.79–2.04) |
| Continuous until index date | 13 (3.7) | 24 (4.4) | 0.86 (0.42–1.78) |
| Non-continuous      | 25 (7.1) | 25 (4.6) | 1.66 (0.91–3.04) |
| PPI added after first ASA prescription | 59 (16.9) | 40 (7.4) | 2.29 (1.45–3.63) |

Abbreviations: ASA, acetylsalicylic acid; CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio; PCP, primary care physician; PPI, proton pump inhibitor; PUD, peptic ulcer disease.

aRelative to non-use of a PPI, and adjusted according to sex, age, year of index date, number of PCP visits and specialist referrals in the year before the index date, smoking status, and use of paracetamol and NSAIDs.

doi:10.1371/journal.pone.0101768.t004
Use of ASA and NSAIDs after Diagnosis of Uncomplicated PUD

In total, 52.9% of patients who were current users of ASA at diagnosis of uncomplicated PUD received at least one ASA prescription in the 60 days after their date of diagnosis, and 42.7% received at least two ASA prescriptions in this time period (proxy for continuous use). By 1 year after the date of diagnosis, 70.1% and 61.4% of current users of ASA at diagnosis had received at least one or at least two ASA prescriptions, respectively. Most of these patients received a PPI coprescription with ASA (Table 5). In contrast, only 19.3% (141/730) of current users of ASA at diagnosis were also receiving a PPI at their date of diagnosis. Of current chronic NSAID users (duration of treatment ≥1 year), 49.6% received at least one NSAID prescription in the 60 days after diagnosis, and 84.7% of these also received at least one PPI prescription. At their date of diagnosis, 20.3% (56/276) of current users of an NSAID were also receiving a PPI.

Discussion

Few epidemiologic studies have investigated predictors of uncomplicated PUD separately from predictors of complicated PUD. Identification of patients at risk of uncomplicated PUD is clinically relevant, given that initially uncomplicated PUD may develop into complicated PUD [4,5], and upper GI symptoms potentially associated with uncomplicated PUD may affect patients’ health-related quality of life and adherence to therapy with ASA and NSAIDs [7–9]. Our results indicate that development of uncomplicated PUD is associated with the use of ASA, dual antiplatelet therapy, NSAIDs, paracetamol, PPIs, H2RAs, selective serotonin reuptake inhibitors, tricyclic antidepressants, antihypertensives and long-term use of oral corticosteroids; and with smoking, frequent use of healthcare services, social deprivation, stress, depression and upper GI symptoms. We also found that about 30% of patients who were current users of ASA or chronic users of NSAIDs when diagnosed with uncomplicated PUD did not receive another prescription of their medication in the year after diagnosis.

Many of the factors that were observed in the present study to increase the risk of uncomplicated PUD have also been demonstrated to increase the risk of complications of PUD. Previous studies have reported an increased risk of upper GI bleeding associated with smoking [3,22–24], use of ASA or NSAIDs [13,14,22,23,25,26], use of high doses of oral corticosteroids [22] and with use of selective serotonin reuptake inhibitors [25,27].

Our results confirm evidence from previous observational studies that reported an increased risk of uncomplicated PUD associated with ASA and NSAID use [4,28,29]. The observations that we report also indicate that combinations of medications may further increase the risk of uncomplicated PUD. Compared with non-use, current use of dual antiplatelet therapy (ASA and clopidogrel) was associated with an approximately 2.5-fold increased risk of uncomplicated PUD, and use of multiple NSAIDs was associated with an almost 4-fold increased risk, although it should be noted that these estimates are based on low patient numbers. Higher doses of NSAIDs were associated with a higher risk of uncomplicated PUD than lower doses. However, no dose response was observed for ASA when comparing doses of <100 mg daily to doses of 200–300 mg daily, indicating that the elevated risk of uncomplicated PUD associated with ASA use is present across the dose range prescribed for cardioprotection (75–300 mg) and may not be reduced by lowering the dose of ASA.

GI symptoms in individuals receiving ASA or NSAID treatment may be more closely monitored than in non-users of these drugs.
and this might increase the likelihood of ASA or NSAID users eventually being diagnosed with uncomplicated PUD compared with non-users (i.e. detection bias). At the same time, initial symptoms of uncomplicated PUD might lead to early discontinuation of ASA or NSAIDs followed by investigations that ultimately result in diagnosis of uncomplicated PUD (i.e. inverse protopathic bias). We attempted to minimize the effect of these biases by adjusting for health services utilization and GI symptoms in the year before the event, and by using a date earlier than that of the recorded diagnosis as the index date in the case–control analysis. However, it is difficult to predict how these two seemingly opposing biases might have affected our results. Similarly, the positive associations that we observed between uncomplicated PUD development and PPI or H₂RA use may be due to confounding by indication. Thus, the associations with gastroprotective medications, GI symptoms and use of healthcare services are likely to be part of the natural history of uncomplicated PUD, or comorbidities, rather than being factors that directly increase the risk of PUD.

A further analysis supported the assertion that the association with gastroprotective medications was due to confounding. When the use of PPIs was analyzed specifically in naïve users of ASA, the association between PPIs and uncomplicated PUD development was observed only in individuals who received a PPI after their first ASA prescription, not in those who received a PPI at the same time as their first ASA prescription. In patients who received a PPI after their first ASA prescription, the PPI may have been prescribed to treat GI symptoms that had arisen as a result of ASA use.

Our analysis of represcribing of medications after development of uncomplicated PUD showed that about 70% of patients who were current users of ASA at diagnosis received another prescription for ASA in the year after diagnosis. Similar levels of represcribing were observed among patients who were current chronic NSAID users at diagnosis. A previous study has shown that represcription rates for ASA and NSAIDs in the year after upper GI bleeding in Denmark were 43% and 25%, respectively; most patients (approximately 88%) in that study who were represcribed ASA or an NSAID also received a PPI [30]. Similarly, in our analysis, most patients (80–90%) who received ASA or NSAID therapy after diagnosis of uncomplicated PUD received concomitant PPI therapy, in line with evidence-based guidelines [31]. However, only about 20% of current users of ASA or NSAIDs were receiving PPI therapy when diagnosed with uncomplicated PUD, indicating that patients receiving ASA or NSAIDs with other GI risk factors may not be identified and prescribed PPI therapy until uncomplicated PUD or upper GI complications are diagnosed. The patients (approximately 30%) who are current users at diagnosis but do not continue with ASA therapy may include some individuals who require continuous ASA therapy for cardioprotection, leaving them at an increased risk of cardiovascular events [32].

The present study has the strength of using a large primary care database containing a substantial amount of anonymized patient data that is representative of the UK general population, and that has been validated for use in epidemiologic studies [16,18]. It should be noted that no information is recorded about the use of over-the-counter medications. However, prescriptions are free in the UK for patients aged over 60 years, reducing the likelihood of long-term over-the-counter medication use. Misclassification of NSAID or ASA users as non-users due to medications being obtained over the counter would tend to lead to an underestimation of the risk of uncomplicated PUD associated with ASA or NSAID use.

Taken together, the results presented here indicate that use of NSAIDs, ASA (across the cardioprotective dose range) and several other medications are risk factors for uncomplicated PUD. These and other identified risk factors, including smoking, are also risk factors for PUD complications. About 70% of patients who are users of ASA or chronic users of NSAIDs at diagnosis are represcribed their medication within a year of diagnosis of uncomplicated PUD, most of these patients also receive PPI therapy, in accordance with guidelines [31]. However, the 30% of patients who do not receive another prescription of ASA may include some individuals in need of continuous ASA therapy, who will be at increased risk of cardiovascular events compared with those who continue to receive ASA [32]. For patients with risk factors for uncomplicated PUD, it is important to take preventative measures to reduce the likelihood of ulcer development.

Supporting Information

Table S1 Patient demographics and lifestyle characteristics at the index date, and comorbidities significantly associated with uncomplicated PUD development. (DOC)

Table S2 Medications for which current, past or recent use was significantly associated with uncomplicated PUD development. (DOC)

Table S3 Medications for which current, past or recent use was significantly associated with uncomplicated PUD development when stratified by ulcer location (gastric or duodenal). (DOC)

Table S4 Medication use significantly associated with uncomplicated PUD development, stratified by Helicobacter pylori infection status, in a UK primary care population during 1997–2003. (DOCX)

Table S5 Association between PPI use and uncomplicated PUD development in naïve current ASA users. (DOC)

Acknowledgments

Medical writing support was provided by Dr Carolyn Brechin and Dr Stephen Sweet of Oxford PharmaGenesis Ltd, Oxford, UK.

Author Contributions

Conceived and designed the experiments: AGP MES SJ PN LAGR. Performed the experiments: AGP LAGR MES. Analyzed the data: AGP MES SJ PN LAGR. Wrote the paper: AGP MES SJ PN LAGR.

References

1. García Rodríguez LA, Cattaruzzi C, Troncoso MG, Agostinis L (1998) Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 158: 33–39.

2. Hernández-Díaz S, García Rodríguez LA (2002) Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 55: 157–163.
3. Lau JY, Sung J, Hill C, Henderson C, Howden CW, et al. (2011) Systematic review of the epidemiology of complicated peptic ulcer disease: incidence, recurrence, risk factors and mortality. Dig Dis Sci 56: 102–113.

4. Lassen A, Hallas J, Schaffalitzky de Muckadell OB (2006) Complicated and uncomplicated peptic ulcers in a Danish county 1993–2002: a population-based cohort study. Am J Gastroenterol 101: 945–953.

5. Hernández-Díaz S, Martín-Merino E, García Rodríguez LA (2013) Risk of complications after a peptic ulcer diagnosis: effectiveness of proton pump inhibitors. Dig Dis Sci 58: 1653–1662.

6. Miyake K, Kasumoki M, Ueki N, Nagoya H, Kodaka Y, et al. (2013) Implication of antimicrobial agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for NSAID-associated ulcers complication. Dig Endosc 25: 25–31.

7. Barkun A, Leonardi G (2010) Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med 123: 359–366 e352.

8. Martín-Merino E, Johansson S, Bueno H, García Rodríguez I (2012) Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease. PLoS Med 3: e171–177.

9. Lanas A, Polo-Tomás M, Roncales P, Gonzalez MA, Zapardiel J (2012) Prescription of and adherence to non-steroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients. Am J Gastroenterol 107: 707–714.

10. Cai S, García Rodríguez LA, Massó-González EL, Hernández-Díaz S (2009) Uncomplicated peptic ulcer in the UK: trends from 1997–2005. Aliment Pharmacol Ther 30: 1039–1048.

11. Peterson WL (1991) Helicobacter pylori and peptic ulcer disease. N Engl J Med 324: 1043–1048.

12. Nomura A, Stemmermann GN, Chyou PH, Perez-Perez GI, Blaser MJ (1994) Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 120: 977–981.

13. Gabriel SE, Jaakkimainen L, Bombardier C (1991) Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115: 787–796.

14. García Rodríguez LA, Hernández-Díaz S, de Abajo FJ (2003) Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol 52: 563–571.

15. Yeomans MD (2011) Aspirin: old drug, new uses and challenges. J Gastroenterol Hepatol 26: 426–431.

16. Bourke A, Dattani H, Robinson M (2004) Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 12: 171–177.

17. O’Neil M, Payne G, Read J (1995) Read Codes Version 3: a user led terminology. Methods Inf Med 34: 187–192.

18. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL (2007) Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 16: 393–401.

19. Margolis AV, García Rodríguez LA, Hernández-Díaz S (2009) Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer. Pharmacoepidemiol Drug Saf 18: 900–909.

20. Lubin JH, Gail MH (1984) Bias in selection of controls for case–control analyses of cohort studies. Biometrics 40: 63–75.

21. Townsend P, Phillimore P, Beattie A (1988) Health and deprivation: inequality and the North. London: Croom Helm.

22. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S (2011) Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation 123: 1108–1115.

23. Udd M, Miettinen P, Palms A, Heikkinen M, Janatuinen E, et al. (2007) Analysis of the risk factors and their combinations in acute gastrointestinal ulcer bleeding: a case–control study. Scand J Gastroenterol 42: 1395–1403.

24. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ (2002) Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 16: 597–606.

25. Lin KJ, Hernández-Díaz S, Rodríguez LA (2011) Acid suppressants reduce risk of gastrointestinal bleeding in patients on antiplatelet or anti-inflammatory therapy. Gastroenterology 141: 71–79.

26. Hernández-Díaz S, García Rodríguez LA (2000) Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 160: 2093–2099.

27. de Abajo FJ, García Rodríguez LA, Montero D (1999) Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population-based case–control study. BMJ 319: 1106–1109.

28. García Rodríguez LA, Hernández-Díaz S (2004) Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 159: 23–31.

29. Pilotto A, Franceschi M, Leandro G, Parì F, Cascavilla L, et al. (2004) Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 20: 1091–1097.

30. Dall M, Depont Christensen R, Schaffalitzky de Muckadell OB, Lassen AT, Hallas J (2012) Re-prescribing of causative drugs in persons discharged after serious drug-induced upper gastrointestinal bleeding. Aliment Pharmacol Ther 35: 948–954.

31. Bhatt DL, Schreiman J, Abraham NS, Antman EM, Chan FK, et al. (2008) ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 118: 1894–1909.

32. García Rodríguez LA, Cea-Soriano L, Martín-Merino E, Johansson S (2011) Discontinuation of low dose aspirin and risk of myocardial infarction: case–control study in UK primary care. BMJ 343: d4094.